Lakefront offloads its shelved CAR-T pipeline to Stoffels-backed Armed Cell
- Lakefront Biotherapeutics, the former Galapagos, is selling its abandoned cell therapy programs to Armed Cell Therapeutics, a new Belgian company co-founded and chaired by ex-Galapagos CEO Paul Stoffels.
- Reported terms are a small upfront payment (single-digit millions of euros) plus up to roughly $230 million in milestones.
- The package covers two armed CAR-Ts nearing the clinic in non-Hodgkin lymphoma and small cell lung cancer, plus three early preclinical projects.
💡 Points
A tiny upfront against a long milestone tail is what a buyer pays for preclinical assets nobody else wanted: the risk stays with Armed Cell, and Lakefront gets optionality without cost. For Lakefront, the signal is a clean pivot to autoimmune T-cell engagers. The open question is whether Armed Cell, run by the man who started the CAR-T bet, can fund the clinic.
Rebranded Galapagos finally finds buyer for unwanted cell therapy pipeline ↗